Companies:
53,025
Total Market Cap:
168995800986035.08
Global Rank
#25980
Country Rank
#334
Market Cap
100.8 M
Price
0.41
Change (%)
1.06%
Volume
416,065
Cantargia AB (publ)'s latest marketcap:
100.8 M
As of 04/30/2026, Cantargia AB (publ)'s market capitalization has reached $100.8 M. According to our data, Cantargia AB (publ) is the 25980th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 100.8 M |
| Revenue (ttm) | 34.13 M |
| Net Income (ttm) | 15.84 M |
| Shares Out | 248.61 M |
| EPS (ttm) | 0.06 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/19/2026 |
Market Cap Chart
Data Updated: 04/30/2026
Cantargia AB (publ)'s yearly market capitalization.
Cantargia AB (publ) has seen its market value grow from kr128.31 M to kr536.5 M since 2015, representing a total increase of 318.14% and an annual compound growth rate (CAGR) of 14.72%.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 06/01/2026 | kr536.5 M | $58.29 M | -48.43% | n/a |
| 12/30/2025 | kr1.04 B | $110.08 M | 147.63% | 32507 |
| 12/30/2024 | kr420.15 M | $37.77 M | -38.81% | 29920 |
| 12/29/2023 | kr686.62 M | $67.7 M | 33.5% | 25702 |
| 12/30/2022 | kr514.32 M | $49.07 M | -72.19% | 26991 |
| 12/30/2021 | kr1.85 B | $203.45 M | -68.27% | 18756 |
| 12/30/2020 | kr5.83 B | $0 | 297.4% | 9733 |
| 12/30/2019 | kr1.47 B | $155.94 M | 56.09% | 15902 |
| 12/28/2018 | kr939.84 M | $105.64 M | 212.84% | 17006 |
| 12/29/2017 | kr300.42 M | $36.53 M | 114.36% | 23075 |
Company Profile
About Cantargia AB (publ)
Cantargia AB (publ) is a biotechnology company focused on developing innovative antibody-based treatments for life-threatening diseases.
Key Developments
- CAN04 (nadunolimab): An IL1RAP-binding antibody currently in Phase II clinical trials for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer.
- CAN10: A preclinical-stage antibody targeting IL1RAP for autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis.
- CANxx Platform: An IL1RAP-based antibody development platform for future therapeutic applications.
Strategic Collaborations
The company has established partnerships with:
- Patheon Biologics B.V. and BioWa Inc. for manufacturing CAN04
- GEICAM (Spanish breast cancer group) for clinical development
Founded: 2009
Headquarters: Lund, Sweden
Frequently Asked Questions
-
What is Cantargia AB (publ)'s (STO-CANTA) current market cap?As of 04/30/2026, Cantargia AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $100.8 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Cantargia AB (publ) (STO-CANTA) rank globally by market cap?Cantargia AB (publ) global market capitalization ranking is approximately 25980 as of 04/30/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.